Trial Profile
Immunogenicity and Safety of GSK Biologicals' Pandemic Influenza Candidate Vaccine GSK2340272A.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; AS03A; Influenza virus vaccine
- Indications Influenza A virus H1N1 subtype; Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 02 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClnicalTrials.gov.
- 22 Sep 2009 Additional location (Germany) identified as reported by ClinicalTrials.gov.
- 22 Sep 2009 Status changed from not yet recruiting to active, no longer recruiting.